Skip to main content
OpenTrials
Completed

NCT Number: NCT00158665

A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

The purpose of the study was to find out if children 5 through 8 years of age who are getting influenza vaccine for the first time should get one or two doses.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Group Health Research Institute

Seattle, Washington, 98101, United States

About this study

Currently, two doses of influenza vaccine are recommended for children younger than 9 years receiving influenza vaccine for the first time. While the scientific support for 2 doses of vaccine in infants and toddlers is sound, the need for 2 doses of vaccine for adequate immunogenicity in older children is less certain. If the immunogenicity of a one-dose vaccine regimen is comparable to a two-dose regimen, then one dose would be preferable for reasons of safety, practicality and economics, and would reduce a major barrier to vaccination in this injection-adverse age group. This study compared the immunogenicity and reactogenicity of one versus two doses of influenza vaccine in children aged 5 to 8 years old receiving influenza vaccine for the first time. All children enrolled in the study received two doses of vaccine, and the immune response after one dose of vaccine was compared to the immune response after two doses of vaccine.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Immunocompetent children who are at least 5 and no more than 8 years of age on the date of the first vaccination.
  • Parents able to give informed consent and child available for all study visits.
  • Family able to understand and comply with planned study procedures.
  • Family must have telephone accessibility.

Exclusion criteria

  • Previous receipt of influenza vaccine of any kind (shot or nasal spray).
  • Active cancer or blood system abnormalities such as leukemia.
  • Immunocompromising illnesses or current receipt of immunosuppressive agents
  • Allergy to eggs or egg protein, or to gentamicin (an antibiotic that is present in trace amounts in the vaccine).
  • Any acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses.

Temporary Exclusion Criteria:

Acute disease, defined as the presence of moderate or severe illness with or without fever, at the time of enrollment. Influenza vaccine may be administered to children with minor illnesses, such as diarrhea, mild upper respiratory infection and low-grade febrile illness with an oral temperature <100.4 F.

Treatment and study plan

2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine

Biological

2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine

Primary outcomes

  1. Comparison of antibody response after 1 dose of influenza vaccine with that after 2 doses of influenza vaccine.

    Time frame: Blood samples were obtained at 3 time points, before dose 1 of vaccine, 4 weeks after receipt of dose 1 and before dose 2, and 4 weeks after dose 2 of vaccine.

Secondary outcomes

  1. To describe and compare the safety profile after 1 and 2 doses of vaccine.

    Time frame: Study diaries were kept from the day of vaccination daily for the 4 days after vaccination.

Sponsors and collaborators

Lead sponsor

Kaiser Permanente

Other

Collaborators

  • Centers for Disease Control and Prevention

Registry information

Official study title

A Comparison of One Versus Two Doses of Influenza Vaccine in Children Aged 5-8 Years of Age Receiving Influenza Vaccine for the First Time

Important dates

Study start
2004
Primary completion
2004
Study completion
2004
First posted
Sep 12, 2005
Registry last updated
Oct 13, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.